AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11517825 — intervention group
Group type: COMPARATOR
Intervention: High-sodium diet (250 mmol Na/day)
Number of subjects: 13
Study 8959788 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms four times daily)
Number of subjects: 40
Study 8959788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8959788 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 40
Study 1493985 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily for three days
Number of subjects: 42
Study 1493985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 4019951 — intervention group
Group type: EXPERIMENTAL
Intervention: PRW A greater than 500,000
Number of subjects: 21
Study 4019951 — intervention group
Group type: EXPERIMENTAL
Intervention: PRW B 200,000 to 20,000,000
Number of subjects: 21
Study 4019951 — intervention group
Group type: EXPERIMENTAL
Intervention: PRW C greater than 20,000,000
Number of subjects: 21
Study 31981294 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Treatment (AOT)
Number of subjects: 8
Study 31981294 — intervention group
Group type: COMPARATOR
Intervention: Videogame Observation Treatment (VOT)
Number of subjects: 8
Study 29174128 — intervention group
Group type: EXPERIMENTAL
Intervention: IUI with ovarian stimulation (oral clomifene citrate 50-150 mg or oral letrozole 2.5-7.5 mg, days 2-6)
Number of subjects: 201
Study 29174128 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (advised to be sexually active around ovulation)
Number of subjects: 201
Study 27000324 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured physical activity (walking 150 min/week, strength, flexibility, and balance training)
Number of subjects: 1635
Study 27000324 — intervention group
Group type: COMPARATOR
Intervention: Health education (workshops and upper extremity stretching exercises)
Number of subjects: 1635
Study 25495953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/d) for 8 weeks
Number of subjects: 34
Study 23128104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1-g capsules containing ≥840 mg n-3-PUFAs as ethyl esters) with preoperative loading of 10 g over 3 to 5 days followed by 2 g/d until hospital discharge or postoperative day 10.
Number of subjects: 1516
Study 23128104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516
Study 23128104 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 1516
Study 20975369 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-RM DP
Number of subjects: 0
Study 20975369 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-RM AP
Number of subjects: 0
Study 20975369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-RM DP
Number of subjects: 0
Study 20975369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-RM AP
Number of subjects: 0
Study 20975369 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-RM loads
Number of subjects: 0
Study 20975369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-RM loads
Number of subjects: 0
Study 18539225 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-care intervention
Number of subjects: 36059
Study 18539225 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-care intervention
Number of subjects: 36059
Study 18539225 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 36059
Study 16858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 600 mg/d
Number of subjects: 39
Study 16858958 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 1200 mg/d
Number of subjects: 39
Study 12456910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus (Elidel, SDZ ASM 981) cream 1%
Number of subjects: 403
Study 12456910 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 403
Study 12456910 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus (Elidel, SDZ ASM 981) cream 1% (after all patients switched at week 6)
Number of subjects: 403
Study 10878516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin (400 mg every 12 hours)
Number of subjects: 32
Study 10878516 — intervention group
Group type: COMPARATOR
Intervention: Intravenous imipenem-cilastatin (500 mg every 6 hours)
Number of subjects: 32
Study 7727089 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral functional endoscopic sinus surgery (FESS) in piglets
Number of subjects: 84
Study 7727089 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic examination of sinus bone in children
Number of subjects: 84
Study 2447198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus strains
Number of subjects: 0
Study 2447198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31476897 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) and percutaneous coronary intervention
Number of subjects: 1660
Study 31476897 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR) and coronary artery bypass grafting
Number of subjects: 1660
Study 31476897 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1660
Study 31476897 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1660
Study 28087146 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1754
Study 28087146 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 1754
Study 25686520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 207
Study 25686520 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents
Number of subjects: 207
Study 25686520 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 207
Study 24043284 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (Bifidobacterium lactis plus inulin) added to breast milk or mixed feeding
Number of subjects: 100
Study 24043284 — intervention group
Group type: COMPARATOR
Intervention: Placebo (breast milk or mixed feeding)
Number of subjects: 100
Study 21170802 — intervention group
Group type: EXPERIMENTAL
Intervention: Taekwondo training (50 min a day, 2 days per week for 12 weeks)
Number of subjects: 31
Study 21170802 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 31
Study 18974654 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary predialysis care (MDC)
Number of subjects: 151
Study 18974654 — intervention group
Group type: COMPARATOR
Intervention: Conventional or no nephrologist-based care
Number of subjects: 151
Study 20850296 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery followed by chemotherapy
Number of subjects: 479
Study 20850296 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval debulking surgery
Number of subjects: 479
Study 20850296 — intervention group
Group type: COMPARATOR
Intervention: Overall quality of pathology reports
Number of subjects: 479
Study 16518708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1000 mg extended-release once-daily
Number of subjects: 19
Study 16518708 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg immediate-release twice-daily
Number of subjects: 19
Study 12131610 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklets
Number of subjects: 59
Study 12131610 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 59
Study 12131610 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklets (newly diagnosed or less informed patients)
Number of subjects: 59
Study 9611155 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 12
Study 9611155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7798614 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% retinoic acid (RA) applied once a day for 4 days
Number of subjects: 0
Study 7798614 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 7798614 — intervention group
Group type: EXPERIMENTAL
Intervention: RA-treated Langerhans cells
Number of subjects: 0
Study 7798614 — intervention group
Group type: EXPERIMENTAL
Intervention: RA treatment
Number of subjects: 0
Study 7798614 — intervention group
Group type: COMPARATOR
Intervention: Anti-CD11c antibody
Number of subjects: 0
Study 3044666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic clamp
Number of subjects: 12
Study 3044666 — intervention group
Group type: COMPARATOR
Intervention: Placebo clamp (0.9% NaCl)
Number of subjects: 12
Study 3044666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic clamp in diabetic subjects
Number of subjects: 12
Study 3044666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemic, euglycaemic clamp in one diabetic subject
Number of subjects: 12
Study 11961625 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument Positioner (PASSIST)
Number of subjects: 78
Study 11961625 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument Positioner (AESOP)
Number of subjects: 78
Study 11961625 — intervention group
Group type: COMPARATOR
Intervention: Surgical Assistant (Control)
Number of subjects: 78
Study 11961625 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire on difficulties and comfort of use
Number of subjects: 78
Study 31173138 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Transnasal Trans-Sphenoidal Surgery (ETSS)
Number of subjects: 187
Study 28984041 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 0.9 mg/day
Number of subjects: 0
Study 28984041 — intervention group
Group type: COMPARATOR
Intervention: additional OAD
Number of subjects: 0
Study 27289127 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized model predictive control (MPC)
Number of subjects: 20
Study 27289127 — intervention group
Group type: COMPARATOR
Intervention: Proportional integral derivative (PID)
Number of subjects: 20
Study 24781571 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous saline injection to increase arterial depth from <2 mm to 2-4 mm
Number of subjects: 60
Study 24781571 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous arterial depth of 2-4 mm
Number of subjects: 60
Study 24781571 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 22573126 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose treatment
Number of subjects: 1368
Study 22573126 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive individuals at baseline)
Number of subjects: 1368
Study 22573126 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity at baseline
Number of subjects: 1368
Study 22573126 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening of glucose tolerance
Number of subjects: 1368
Study 20227301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil at 40 mg 3 times daily
Number of subjects: 18
Study 19326341 — intervention group
Group type: COMPARATOR
Intervention: Double-dose antioxidant supplement
Number of subjects: 60
Study 19326341 — intervention group
Group type: COMPARATOR
Intervention: Gamma-tocopherol (5 and 50 microM for 23 hours)
Number of subjects: 60
Study 16055637 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus expressed by descriptive adjectives (large vs. small)
Number of subjects: 0
Study 16055637 — intervention group
Group type: EXPERIMENTAL
Intervention: Large sources
Number of subjects: 0
Study 16055637 — intervention group
Group type: EXPERIMENTAL
Intervention: Small minority
Number of subjects: 0
Study 16055637 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus expressed in terms of descriptive adjectives (large, small)
Number of subjects: 0
Study 16055637 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus expressed in terms of percentages (82%, 18%, 52%, 48%)
Number of subjects: 0
Study 12376522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash (swish)
Number of subjects: 22
Study 12376522 — intervention group
Group type: COMPARATOR
Intervention: Cytobrush
Number of subjects: 22
Study 12376522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash
Number of subjects: 22
Study 12376522 — intervention group
Group type: COMPARATOR
Intervention: Cytobrush with variations (rubbing cheeks, morning collection)
Number of subjects: 22
Study 10197402 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ignoring treatment
Number of subjects: 0
Study 10197402 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated ignoring treatment
Number of subjects: 0
Study 10197402 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 8530300 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets relatively high in non-starch polysaccharide (NSP)
Number of subjects: 136
Study 8530300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diets
Number of subjects: 136
Study 8530300 — intervention group
Group type: COMPARATOR
Intervention: Control group (remainder of the sample)
Number of subjects: 136
Study 2132137 — intervention group
Group type: EXPERIMENTAL
Intervention: Bretylium 10 mg/kg
Number of subjects: 33
Study 2132137 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg
Number of subjects: 33
Study 2132137 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 33
Study 358527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride 10 mg
Number of subjects: 106
Study 358527 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin chloride 20 mg
Number of subjects: 106
Study 358527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 31220505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise protocol (aerobic and resistance training)
Number of subjects: 32
Study 28778550 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CE)
Number of subjects: 12
Study 28778550 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte‐protein solution (CEP)
Number of subjects: 12
Study 28778550 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (DW)
Number of subjects: 12
Study 26032216 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically induced muscle cramps (EIMCs) applied twice a week, 3x6 EIMCs of 5 seconds each
Number of subjects: 15
Study 26032216 — intervention group
Group type: COMPARATOR
Intervention: Control group (nCP) with ankle fixed at 0° plantar flexion
Number of subjects: 15
Study 26032216 — intervention group
Group type: COMPARATOR
Intervention: Control group (nCP)
Number of subjects: 15
Study 22788697 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment applied to affected nails for 12 weeks
Number of subjects: 21
Study 22788697 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated nails on the other hand)
Number of subjects: 21
Study 21775557 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-enriched essential amino acids (L-EAA) - 10 g EAA with 3.5 g leucine
Number of subjects: 8
Study 21775557 — intervention group
Group type: COMPARATOR
Intervention: Essential amino acids (EAA) - 10 g EAA with 1.87 g leucine
Number of subjects: 8
Study 19627358 — intervention group
Group type: EXPERIMENTAL
Intervention: XP Bond/CoreXFlow + DT Light‐Post
Number of subjects: 84
Study 19627358 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0 + Tech 21
Number of subjects: 84
Study 19627358 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem + RelyX
Number of subjects: 84
Study 19627358 — intervention group
Group type: COMPARATOR
Intervention: Control specimens (stored in artificial saliva)
Number of subjects: 84
Study 17108753 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 73
Study 17108753 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed material intervention
Number of subjects: 73
Study 17108753 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 73
Study 12745494 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization as a teachable moment for quitting
Number of subjects: 2350
Study 12745494 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2350
Study 12745494 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of change
Number of subjects: 2350
Study 12745494 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first cigarette
Number of subjects: 2350
Study 10964636 — intervention group
Group type: EXPERIMENTAL
Intervention: ER tie-in
Number of subjects: 458
Study 10964636 — intervention group
Group type: COMPARATOR
Intervention: No tie-in
Number of subjects: 458
Study 8783540 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline alone for maintenance of peripheral intravenous access devices
Number of subjects: 0
Study 8783540 — intervention group
Group type: COMPARATOR
Intervention: Heparinized saline for maintenance of peripheral intravenous access devices
Number of subjects: 0
Study 1619996 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium supplementation (250 micrograms of chromium orally as chromium chloride)
Number of subjects: 76
Study 1619996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 6714820 — intervention group
Group type: EXPERIMENTAL
Intervention: Orgotein (Superoxide Dismutase)
Number of subjects: 31
Study 6714820 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (Corticoid)
Number of subjects: 31
Study 6714820 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Orgotein and Corticoid)
Number of subjects: 31
Study 6714820 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint diameter, strength of pinch-grip, range of motion
Number of subjects: 31
Study 30777080 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance review and facilitated feedback intervention
Number of subjects: 108
Study 30777080 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 108
Study 30064991 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (3 μg/kg/day), subcutaneous, once daily for 4 days
Number of subjects: 38
Study 30064991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 30064991 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 38
Study 26867541 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restricted exercise (BFR exercise group)
Number of subjects: 32
Study 26867541 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise (control exercise group)
Number of subjects: 32
Study 24579075 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus acidophilus, Lactobacillus delbrueckii subsp. bulgaricus, and Bifidobacterium bifidus)
Number of subjects: 43
Study 22514718 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmaceutical interventions (NPIs)
Number of subjects: 0
Study 22514718 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of respiratory specimens from individuals reporting ARI
Number of subjects: 0
Study 22514718 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection of specimens only from individuals reporting febrile ARI
Number of subjects: 0
Study 22514718 — intervention group
Group type: EXPERIMENTAL
Intervention: Collection and testing of sera before and after influenza activity
Number of subjects: 0
Study 22514718 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR testing
Number of subjects: 0
Study 22514718 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine collection of specimens for RT-PCR testing
Number of subjects: 0
Study 20110153 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfimeprase (0.3 mg/kg)
Number of subjects: 402
Study 20110153 — intervention group
Group type: COMPARATOR
Intervention: Intrathrombus placebo (IT)
Number of subjects: 402
Study 20110153 — intervention group
Group type: COMPARATOR
Intervention: Perithrombus placebo (PT)
Number of subjects: 402
Study 18051617 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P-group training
Number of subjects: 280
Study 16076989 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea‐caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine per day)
Number of subjects: 76
Study 16076989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 16076989 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea‐caffeine mixture
Number of subjects: 76
Study 16076989 — intervention group
Group type: EXPERIMENTAL
Intervention: High caffeine consumers
Number of subjects: 76
Study 12399201 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Number of subjects: 64
Study 12399201 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Number of subjects: 64
Study 12399201 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Number of subjects: 64
Study 12399201 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micro g of purified non‐adsorbed hepatitis B surface antigen (HBsAg)
Number of subjects: 64
Study 9602578 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming using forced air for 30 min before induction of general anaesthesia and during anaesthesia
Number of subjects: 40
Study 9602578 — intervention group
Group type: COMPARATOR
Intervention: Passive protection against heat loss (circulating water mattresses, blankets, fluid warming devices)
Number of subjects: 40
Study 9602578 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming
Number of subjects: 40
Study 9602578 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 7746026 — intervention group
Group type: EXPERIMENTAL
Intervention: Eferox 100 tablets (100 micrograms levothyroxine‐Na)
Number of subjects: 24
Study 7746026 — intervention group
Group type: COMPARATOR
Intervention: Reference preparation (100 micrograms levothyroxine‐Na)
Number of subjects: 24
Study 2646206 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once a day
Number of subjects: 281
Study 2646206 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 500 mg twice a day
Number of subjects: 281